Biosimilars are near-replicas of biologic drugs made from living cells
SEOUL—Samsung Group’s biologic drug development affiliate said Tuesday that it submitted a near-replica of blockbuster breast cancer drug Herceptin for regulatory approval in Europe, underscoring the South Korean conglomerate’s growing ambitions in the field of biosimilars.
23:35 Mexico's 'El Chapo': From Selling Candy To Selling Drugs11
15:02 U.S housing starts surge in December; jobless claims near 43-year low13
03:35 Ivan Rodriguez, Tim Raines and Jeff Bagwell prove Hall of Fame does forgive16
08:15 UK premier to signal EU clean break: no 'partial membership'15